OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analysts have given OPKO Health an average recommendation of "Hold" across seven brokerages (1 sell, 3 hold, 2 buy, 1 strong buy) with a consensus 12‑month target price of about $2.03.
• Coverage is mixed and recently tilted negative—Wall Street Zen and Weiss Ratings moved to sell, Barrington cut its price target to $1.50 despite an "outperform" call, and JPMorgan rates the stock neutral.
• The stock opened around $1.19, has a market cap of about $903M, is unprofitable with a negative net margin and ROE and revenue down ~19% year‑over‑year, while institutional investors own roughly 64.6% of the shares.

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $2.0333.

Several equities research analysts have weighed in on the stock. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, January 22nd. Barrington Research dropped their price objective on shares of OPKO Health from $2.25 to $1.50 and set an "outperform" rating for the company in a research report on Monday, March 2nd. Finally, JPMorgan Chase & Co. assumed coverage on OPKO Health in a report on Thursday, November 20th. They set a "neutral" rating on the stock.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently made changes to their positions in OPK. Geode Capital Management LLC raised its holdings in OPKO Health by 23.7% during the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company's stock worth $13,763,000 after purchasing an additional 1,995,633 shares during the last quarter. Tejara Capital Ltd boosted its stake in shares of OPKO Health by 10.0% in the 2nd quarter. Tejara Capital Ltd now owns 946,090 shares of the biotechnology company's stock valued at $1,249,000 after purchasing an additional 85,746 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of OPKO Health by 94.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 391,664 shares of the biotechnology company's stock worth $517,000 after buying an additional 190,319 shares during the period. New York State Common Retirement Fund grew its position in shares of OPKO Health by 115.3% during the 3rd quarter. New York State Common Retirement Fund now owns 130,901 shares of the biotechnology company's stock worth $203,000 after buying an additional 70,100 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of OPKO Health by 45.8% during the third quarter. Arizona State Retirement System now owns 128,608 shares of the biotechnology company's stock worth $199,000 after buying an additional 40,414 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Price Performance

OPKO Health stock opened at $1.19 on Tuesday. The business's fifty day moving average is $1.25 and its two-hundred day moving average is $1.34. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.52 and a current ratio of 3.97. The firm has a market cap of $903.29 million, a P/E ratio of -3.97 and a beta of 1.50. OPKO Health has a 52 week low of $1.11 and a 52 week high of $1.87.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company had revenue of $148.50 million during the quarter, compared to analyst estimates of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm's quarterly revenue was down 19.1% compared to the same quarter last year. During the same period last year, the company posted $0.01 earnings per share. Equities research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.